Skip to main content
Premium Trial:

Request an Annual Quote

Fitch Affirms Life Technologies Rating

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its 'BBB' issuer default rating with a stable outlook on Life Technologies.

The New York-based ratings firm said that the rating is supported by a general declining trend in Life Tech's debt leverage over the past three years. It noted that the reduction in leverage is due to a combination of stable operating performance and use of cash for debt reduction.

As of Sept. 30, 2011, Life Tech's leverage was 2.4x, a "substantial" decline from around 3.5x following the merger of Applied Biosystems and Invitrogen to form Life Tech, Fitch said in a statement.

Fitch said that it expects Life Tech's total debt to decline further during this quarter due to a planned redemption of $450 million convertible notes due 2024.

Fitch also noted in its statement recent consolidation activity in the genomics tools field and said that it believes Life Tech may increase its M&A activity in 2012. "Maintenance of the 'BBB' IDR for Life Technologies contemplates debt-to-EBITDA maintained between 2.0x and 2.5x in the near to medium term, although periodic increases to fund acquisitions could be tolerated within the current rating category," the ratings firm said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.